A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

导出 OA

翻译打印收藏纠错

作者： Linus,Backert ^[1] ; Daniel Johannes,Kowalewski ^[2] ; Simon,Walz ^[1] ; Heiko,Schuster ^[3] ; Claudia,Berlin ^[1] ; Marian Christoph,Neidert ^[4] ; Mirle,Schemionek ^[1] ; Tim H,Brümmendorf ^[3] ; Vladan,Vucinic ^[1] ; Dietger,Niederwieser ^[4] ; Lothar,Kanz ^[5] ; Helmut Rainer,Salih ^[6] ; Oliver,Kohlbacher ^[6] ; Katja,Weisel ^[7] ; Hans-Georg,Rammensee ^[7] ; Stefan,Stevanovic ^[4] ; Juliane Sarah,Walz ^[4]

作者单位： Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. ^[1] Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany. ^[2] Immatics Biotechnologies GmbH, Tübingen, Germany. ^[3] Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany. ^[4] Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. ^[5] Department of Hematology, Oncology, Hemostaseology and SCT, University Hospital RWTH Aachen, Aachen, Germany. ^[6] University Hospital Leipzig, Department of Hematology and Oncology, Leipzig, Germany. ^[7] Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany. ^[8] Quantitative Biology Center, University of Tübingen, Tübingen, Germany. ^[9] Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany. ^[10] German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany. ^[11]

关键词 HLA cancer immunotherapy hematological malignancies mass spectrometry tumor antigen